BIODESIX, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
BIODESIX, INC. (BDSX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $7.70 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-05
- BIODESIX, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $7.66, a 732.61% increase year-over-year.
- BIODESIX, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.92, a 46.51% decline year-over-year.
- BIODESIX, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $1.72, a 12.69% decline year-over-year.
- BIODESIX, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $1.97, a 46.61% decline year-over-year.
- BIODESIX, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $16.07, a 862.28% increase from fiscal 2024.
- BIODESIX, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $1.67, a 8.74% decline from fiscal 2023.
- BIODESIX, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $1.83, a 37.33% decline from fiscal 2022.
- BIODESIX, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $2.92, a 83.66% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.70 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | $7.66 10-Q · filed 2026-05-04 | |||
| 2025-12-31 | $16.07 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $16.50 10-Q · filed 2025-11-03 | |||
| 2025-06-30 | $0.84 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $0.92 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $1.67 10-K · filed 2025-03-03 | |||
| 2024-09-30 | $1.67 10-Q · filed 2024-11-01 | |||
| 2024-06-30 | $1.67 10-Q · filed 2024-08-07 | |||
| 2024-03-31 | $1.72 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | $1.83 10-K · filed 2024-03-01 | |||
| 2023-09-30 | $1.85 10-Q · filed 2023-11-07 | |||
| 2023-06-30 | $1.94 10-Q · filed 2023-08-07 | |||
| 2023-03-31 | $1.97 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $2.92 10-K · filed 2023-03-06 | |||
| 2022-09-30 | $3.15 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $3.37 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $3.69 10-Q · filed 2022-05-11 | |||
| 2021-12-31 | $17.87 10-K · filed 2022-03-14 | |||
| 2021-09-30 | $18.80 10-Q · filed 2021-11-15 | |||
| 2021-06-30 | $19.39 10-Q · filed 2021-08-10 | |||
| 2021-03-31 | $20.55 10-Q · filed 2021-05-11 | |||
| 2020-12-31 | $2.81 10-K · filed 2021-03-16 | |||
| 2020-09-30 | $2.67 10-Q · filed 2020-12-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |